Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00071396 | Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders | completed | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00267059 |
| Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) |
| completed |
| Phase 2 |
| 45 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Aug 7, 2012 |
| clinicaltrials |
| NCT00038831 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00102661 | Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00562770 | Oral Valganciclovir Versus Valacyclovir | completed | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01098188 | LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia | completed | Phase 1 | 33 | Laboratoire français de Fractionnement et de BiotechnologiesINDUSTRY | 1 | Apr 30, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT01082939 | Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 23, 2012 | clinicaltrials |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00036257 | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00934986 | Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia(LLC-NK) | completed | N/A | 70 | Institut Paoli-CalmettesOTHER | 1 | Sep 14, 2011 | clinicaltrials |
| NCT01423032 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 96 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00481858 | Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis(CRC011) | completed | — | 150 | KineMedINDUSTRY | 1 | Feb 28, 2011 | clinicaltrials |
| NCT00772811 | Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma(Flu-Mel) | completed | Phase 2 | 38 | Cooperative Study Group A for HematologyNETWORK | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00285103 | SPC2996 in Chronic Lymphocytic Leukaemia | completed | Phase 1 / Phase 2 | 46 | Santaris Pharma A/SINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT01021358 | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | completed | Phase 1 | 12 | AbbottINDUSTRY | 1 | Dec 20, 2010 | clinicaltrials |
| NCT00743028 | Assess the Oral Bioavailability of New ABT-263 Formulations | completed | Phase 1 | 36 | AbbottINDUSTRY | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00286780 | Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 19 | Ascenta TherapeuticsINDUSTRY | 1 | Aug 13, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00292760 | A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion | completed | Phase 2 | — | Royal Marsden NHS Foundation TrustOTHER | 0 | Dec 16, 2009 | clinicaltrials |
| NCT00021749 | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 40 | Genta IncorporatedINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00783588 | A Phase I Extension Trial of Repeated Infusions of ISF35 | completed | Phase 1 | 4 | Memgen, LLCINDUSTRY | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00779883 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | completed | Phase 1 | 9 | Memgen, LLCINDUSTRY | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00145652 | Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | completed | Phase 3 | 66 | Sundsvall HospitalOTHER | 1 | Jul 30, 2007 | clinicaltrials |
| NCT00058656 | Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | completed | Phase 1 / Phase 2 | 18 | Xcyte TherapiesINDUSTRY | 1 | Nov 22, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Aug 31, 2012source: clinicaltrials